Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice - PubMed (original) (raw)

Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice

S Agrawal et al. Proc Natl Acad Sci U S A. 1991.

Abstract

We describe preliminary studies of the pharmacokinetics, biodistribution, and excretion of an oligodeoxy-nucleotide phosphorothioate ([S]oligonucleotide) in mice. After either intravenous or intraperitoneal administration of a single dose (30 mg/kg of body weight), [S]oligonucleotide (35S-labeled at each internucleotide linkage) was found in most of the tissues for up to 48 hr. About 30% of the dose was excreted in urine within 24 hr, irrespective of the mode of administration; the excreted [S]oligonucleotide was found to be extensively degraded. In plasma, stomach, heart, and intestine, the [S]oligonucleotide was degraded by only 15%, whereas in the kidney and liver degradation was about 50% in 48 hr. The surprising observation was made that chain length extension of administered [S]oligonucleotide occurred in kidney, liver, and intestine. These results provide an initial definition of parameters for the pharmaceutical development of antisense oligonucleotides.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7448-51 - PubMed
    1. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7079-83 - PubMed
    1. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4143-6 - PubMed
    1. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5507-11 - PubMed
    1. J Biochem Biophys Methods. 1986 Sep;13(2):97-102 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources